Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Equity Income (2023 - 2025)

Perspective Therapeutics' Equity Income history spans 2 years, with the latest figure at -$2000.0 for Q4 2024.

  • For Q4 2024, Equity Income rose 60.0% year-over-year to -$2000.0; the TTM value through Dec 2024 reached -$8000.0, up 52.94%, while the annual FY2024 figure was -$8000.0, 52.94% up from the prior year.
  • Equity Income for Q4 2024 was -$2000.0 at Perspective Therapeutics, up from -$4000.0 in the prior quarter.
  • Across five years, Equity Income topped out at -$2000.0 in Q1 2024 and bottomed at -$12000.0 in Q3 2023.